Wyeth LLC

Wyeth LLC is a pharmaceutical company founded in Philadelphia, Pennsylvania, in 1860 as John Wyeth and Brother. It later operated as American Home Products Corporation before being renamed Wyeth in 2002. Wyeth was a publicly traded company (NYSE: WYE) until its acquisition by Pfizer Inc. in October 2009 in a deal valued at approximately $68 billion. Following the acquisition, Wyeth LLC became a wholly-owned subsidiary of Pfizer. Prior to the merger, Wyeth reported revenues of $22.4 billion in 2008 and had approximately 49,732 employees in 2005. Its headquarters were located in Collegeville, Pennsylvania, and Madison, New Jersey, before consolidating with Pfizer's in New York City.

Historically, Wyeth was a global leader in the research, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals, and non-prescription medicines. Key products included prescription drugs like Premarin, Effexor, and Enbrel (outside North America), as well as over-the-counter medicines such as Robitussin and Advil. Post-acquisition, parts of Wyeth's business were further divested; for example, its infant nutrition division was sold to Nestlé and renamed Wyeth Nutrition, and its consumer healthcare division merged into what became Haleon. Within Pfizer, Wyeth Pharmaceuticals LLC now operates as a legacy branded and specialty biopharma business focused on biologics and immunology-adjacent franchises, managing existing product lines and competing against biosimilar entries.

In patent litigation, Wyeth LLC currently shows a posture of asserting its intellectual property. The company has a record of one tracked case as a plaintiff and zero as a defendant. This indicates that it is not primarily an operating company defending against numerous patent infringement suits, nor is it a traditional non-practicing entity (NPE) with a broad assertion campaign. Instead, the single plaintiff case suggests a strategic enforcement of its pharmaceutical patent portfolio, likely managed under the broader Pfizer corporate structure.

The sole tracked case is Wyeth LLC v. AstraZeneca Pharmaceuticals LP, filed in 2024 at the U.S. Court of Appeals for the Federal Circuit. This appellate level litigation suggests an ongoing dispute related to pharmaceutical patents, aligning with Wyeth's historical focus and current role within Pfizer's legacy portfolio. Wyeth has also been involved in other legal actions, including a 2013 settlement of $490.9 million with the Department of Justice for unlawful marketing of the prescription drug Rapamune for unapproved uses prior to its acquisition by Pfizer.